<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468858</url>
  </required_header>
  <id_info>
    <org_study_id>A-14040</org_study_id>
    <secondary_id>WIRB number 20070071</secondary_id>
    <secondary_id>106405</secondary_id>
    <secondary_id>T-DEN-003</secondary_id>
    <nct_id>NCT00468858</nct_id>
  </id_info>
  <brief_title>A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children</brief_title>
  <official_title>Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of two different
      formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two
      doses are given six months apart to adults and children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, children and adults at multiple sites in Puerto Rico will be randomly
      allocated to receive one of two T-DEN formulations or placebo. Subjects will be stratified by
      age group (a specific number of subjects in each of 4 age groups [12 months to 50 years of
      age] will be enrolled). The study includes 6 scheduled visits and 4 scheduled venipunctures.
      Safety follow-up for dengue may require unscheduled visits and venipunctures.

      &gt; Multiple DEN virus serotypes are endemic in Puerto Rico and all residents are considered to
      be at risk for dengue. The results of this phase II study will provide a basis for
      identifying the vaccine formulations which elicit neutralizing antibodies to all four dengue
      virus serotypes in a high proportion of vaccine recipients. The most immunogenic and well
      tolerated candidate formulation identified in this study will be considered for advancement
      to phase III development.

      &gt;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of All and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within 21 days (days 0-20) f/up period after each vaccine dose</time_frame>
    <description>Incidence of all and grade 3 (prevents normal, everyday activities) solicited local and general symptoms within the 21-day follow-up period (Total vaccinated cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Summary of Unsolicited Adverse Events Within the 31-day Post-vaccination Period</measure>
    <time_frame>Within the 31-day (days 0-30) follow-up period after each vaccine dose</time_frame>
    <description>Summary of unsolicited Adverse Events within the 31-day post-vaccination period by age group (total vaccinated cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Occurrence of Serious Adverse Events (SAEs)</measure>
    <time_frame>6 months + 30 day follow-up period after last vaccine dose</time_frame>
    <description>Summary of SAEs, 6 months + 30 day follow-up period after last vaccine dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Suspected and Laboratory Confirmed Dengue</measure>
    <time_frame>31-day (days 0-30) post-vaccination period and after 31-day period</time_frame>
    <description>Incidence of suspected and confirmed dengue reported during the 31-day (Days 0-30) post-vaccination period and after the 31-day period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs for Antibody Titer Above the Assay Cut Off to Each DEN Serotype for Unprimed and Primed Subjects</measure>
    <time_frame>at month 7 (one month post dose 2)</time_frame>
    <description>Comparison of F17 and F19 formulations in terms of GMTs at month 7 (one month post dose 2) for each DEN type, -unprimed and primed subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Neut. Antibody Titer Above the Assay Cut-off to All Dengue Serotypes</measure>
    <time_frame>Pre-vaccination, at post dose 1, months 3 and 6 and post dose 2, month 7</time_frame>
    <description>Monovalent, bivalent, trivalent and tetravalent response for DEN neut. antibodies for unprimed and primed subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Neut. Sero-response to Each DEN Serotype</measure>
    <time_frame>Pre-accination, at post dose 1, months 3 and 6 and post dose 2, month 7</time_frame>
    <description>Seropositivity rates for DEN neut. antibodies for unprimed and primed subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response to DEN Antibody at Post Dose 1, Month 3</measure>
    <time_frame>at month 3, post dose 1</time_frame>
    <description>Vaccine response for DEN-1, DEN-2, DEN-3 and DEN-4 antibody
S- = seronegative subjects (antibody titer &lt;10 ED50 for DEN-1, 2, 3, and 4 prior to vaccination; S+ = Seropositive subjects (antibody titer &gt;10 ED50 for DEN-1, 2, 3 and 4 prior to vaccination; Total = subjects either seropositive or seronegative at pre-vaccination
Vaccine response defined as: For initially seronegative subjects, antibody titer &gt;10 ED50 at PI(M3) and for initially seropositive subjects: antibody titer at PI(m3) &gt;4 fold the pre-vaccination antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response to DEN Antibody at Post Dose 2, Month 7</measure>
    <time_frame>at month 7, post dose 2</time_frame>
    <description>Vaccine response for DEN-1, DEN2, DEN-3, DEN-4 antibody at post dose 2, month 7</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">636</enrollment>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <condition>Dengue Shock Syndrome</condition>
  <arm_group>
    <arm_group_label>T-DEN-Post-Transfection F17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-Transfection F17, full dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-DEN-Post-Transfection F19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-Transfection F19, full dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-DEN-Post-Transfection F17</intervention_name>
    <description>Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
    <arm_group_label>T-DEN-Post-Transfection F17</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-DEN-Post-Transfection F19</intervention_name>
    <description>Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
    <arm_group_label>T-DEN-Post-Transfection F19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parents/guardians can
             and will comply with the requirements of the protocol (e.g., completion of the diary
             cards, return for follow-up visits) should be enrolled in the study.

          -  A healthy male or non-pregnant female between 12 months (mths) and 50 years (yrs) of
             age at the time of the first vaccination;

          -  Free of obvious health problems as established by medical history and physical
             examination before entering into the study;

          -  For children: 23mths of age, full compliance with the United States Advisory Committee
             on Immunization Practices (U.S. ACIP) recommended childhood immunization schedule;

          -  Written informed consent obtained from the subject or a parent/guardian and assent for
             subjects 7-20 yrs of age;

          -  If the subject is female, she must be of non-childbearing potential, i.e. either
             pre-menarcheal, surgically sterilized or one year post-menopausal; or, if of
             childbearing potential, she must be abstinent or have used adequate contraceptive
             precautions (i.e. intrauterine contraceptive device; condom and spermicide
             combination, oral contraceptives or other equivalent hormonal contraception, e.g.
             progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30
             days (dys) prior to vaccination, have a negative pregnancy test within 48 hrs prior to
             vaccination and must agree to continue such precautions for 60 dys after completion of
             the vaccination series. Any child who begins menarche during the study period must
             follow the same precautions listed above, from menarche until 60 dys after the second
             vaccine dose.

        Exclusion Criteria:

          -  Pregnant or lactating female;

          -  Female planning to become pregnant or planning to discontinue abstinence or
             contraceptive precautions;

          -  History of any neurological or behavioral disorder or seizures, with the exception of
             a single febrile seizure in childhood;

          -  History of allergic disease/reaction likely to be exacerbated by any component of the
             vaccine;

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal,
             hematologic or endocrine functional defect, as determined by physical examination or
             laboratory tests;

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition;

          -  Acute disease at the time of enrollment (acute disease is defined as the presence of a
             moderate or severe illness with or without fever); note that vaccine can be
             administered to persons with a minor illness such as diarrhea, mild upper respiratory
             infection with or without low-grade febrile illness, i.e., equivalent to an oral
             temperature &lt;37.5°C/&lt;99.5°F.

          -  Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;

          -  Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 dys preceding the first dose of study vaccine/placebo or planned use
             during the study period;

          -  Planned administration of a vaccine not foreseen by the study protocol during the
             period starting from 30 dys before each dose of the study vaccine and ending 30 dys
             after; with the exception of standard infant and children &quot;inactivated&quot; vaccines or
             the inactivated influenza vaccine administered to adults or children;

          -  A planned move to a location that will prohibit participating in the trial for the 12
             mth duration;

          -  Chronic administration (defined as more than 14 dys) of immunosuppressants or other
             immune-modifying drugs within 90 dys preceding the first dose or planned
             administration during the study period. For corticosteroids, this will mean
             prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;

          -  Administration of immunoglobulins and/or blood products within 90 dys preceding the
             first dose or planned administration during the study period;

          -  Hypertension;

          -  Chest pain, palpitations, dizziness, shortness of breath unrelated to asthma,
             arrhythmias or friction rubs;

          -  Any chronic systemic drug therapy to be continued during the study period (except for
             vitamin/mineral supplements, routine treatment for gastro-esophageal reflux);

          -  Potential adult volunteers, or parents of potential child volunteers, who do not have
             easy access to a fixed or mobile telephone;

          -  History of chronic alcohol consumption and/or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Bertran-Pasarell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Medicina Interna Seccion Enfermedades Infecciosas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clemente Diaz-Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of PR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ines O. Esquilin-Rivera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of PR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evelyn Matta-Fontanet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Caparra Internal Medicine Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domingo Chardon-Feliciano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ponce School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Morales-Ramirez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research PR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Rodriguez-Carrasquillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice, PR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Rodriguez-Santana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Neumologia pediatrica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Sosa-Padilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice PR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Tavarez-Valle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice, PR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Santiago-Cornier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Quintero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Juan Batista Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Juan Batista Medical School</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Memorial Hospital</name>
      <address>
        <city>Ponce</city>
        <zip>00733</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caparra Internal Medicine Research Center</name>
      <address>
        <city>Rio Grande</city>
        <zip>00745</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMI Clinical Research Center</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torre Medica San Vicente de Paul</name>
      <address>
        <city>San German</city>
        <zip>00683</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research PR</name>
      <address>
        <city>San Juan</city>
        <zip>00909-1711</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Neumologia Pediatricia</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept Pediatria, Esc. De Medicina</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <results_first_submitted>February 8, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <disposition_first_submitted>December 28, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 28, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 1, 2016</disposition_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue</keyword>
  <keyword>Virus</keyword>
  <keyword>Live-attenuated</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Dengue viral infection</keyword>
  <keyword>Dengue Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>GlaxoSmithKline</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T-DEN-Post-Transfection F17</title>
          <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
        </group>
        <group group_id="P2">
          <title>T-DEN-Post-Transfection F19</title>
          <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T-DEN-Post-Transfection F17</title>
          <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
        </group>
        <group group_id="B2">
          <title>T-DEN-Post-Transfection F19</title>
          <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="213"/>
            <count group_id="B4" value="636"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.8" spread="14.10"/>
                    <measurement group_id="B2" value="12.8" spread="12.51"/>
                    <measurement group_id="B3" value="13.6" spread="13.89"/>
                    <measurement group_id="B4" value="13.4" spread="13.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="335"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="635"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>African heritage / African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dominican</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Peruvian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Puerto Rican</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="494"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-Arabic / North African heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Caucasian / European heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Incidence of All and Grade 3 Solicited Local Symptoms</title>
        <description>Incidence of all and grade 3 (prevents normal, everyday activities) solicited local and general symptoms within the 21-day follow-up period (Total vaccinated cohort)</description>
        <time_frame>Within 21 days (days 0-20) f/up period after each vaccine dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-DEN-Post-Transfection F17</title>
            <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O2">
            <title>T-DEN-Post-Transfection F19</title>
            <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Incidence of All and Grade 3 Solicited Local Symptoms</title>
          <description>Incidence of all and grade 3 (prevents normal, everyday activities) solicited local and general symptoms within the 21-day follow-up period (Total vaccinated cohort)</description>
          <units>number of occurances</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Summary of Unsolicited Adverse Events Within the 31-day Post-vaccination Period</title>
        <description>Summary of unsolicited Adverse Events within the 31-day post-vaccination period by age group (total vaccinated cohort)</description>
        <time_frame>Within the 31-day (days 0-30) follow-up period after each vaccine dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-DEN-Post-Transfection F17</title>
            <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O2">
            <title>T-DEN-Post-Transfection F19</title>
            <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Summary of Unsolicited Adverse Events Within the 31-day Post-vaccination Period</title>
          <description>Summary of unsolicited Adverse Events within the 31-day post-vaccination period by age group (total vaccinated cohort)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>At least one symptom - age 1 - 4 years</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At least one symptom - age 5 - 50</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject showing no unsolicited symptoms</title>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Occurrence of Serious Adverse Events (SAEs)</title>
        <description>Summary of SAEs, 6 months + 30 day follow-up period after last vaccine dose</description>
        <time_frame>6 months + 30 day follow-up period after last vaccine dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-DEN-Post-Transfection F17</title>
            <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O2">
            <title>T-DEN-Post-Transfection F19</title>
            <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Occurrence of Serious Adverse Events (SAEs)</title>
          <description>Summary of SAEs, 6 months + 30 day follow-up period after last vaccine dose</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects with at least 1 SAE - not related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject showing no SAE symptoms</title>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="208"/>
                    <measurement group_id="O3" value="202"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects with at least 1 SAE - related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Suspected and Laboratory Confirmed Dengue</title>
        <description>Incidence of suspected and confirmed dengue reported during the 31-day (Days 0-30) post-vaccination period and after the 31-day period</description>
        <time_frame>31-day (days 0-30) post-vaccination period and after 31-day period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>During 31-Day Post Vaccination: F17</title>
            <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O2">
            <title>During 31-Day Post Vaccination: F19</title>
            <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O3">
            <title>During 31-Day Post Vaccination: Placebo</title>
            <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
          </group>
          <group group_id="O4">
            <title>After 31-Day Post Vaccination Period: F17</title>
            <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O5">
            <title>After 31-Day Post Vaccination Period: F19</title>
            <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O6">
            <title>After 31-Day Post-Vaccination Period: Placebo</title>
            <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Suspected and Laboratory Confirmed Dengue</title>
          <description>Incidence of suspected and confirmed dengue reported during the 31-day (Days 0-30) post-vaccination period and after the 31-day period</description>
          <units>dengue fever cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="211"/>
                <count group_id="O5" value="212"/>
                <count group_id="O6" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1: Suspected dengue fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1: Suspected with med. attention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1: Confirmed dengue fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2: Suspected dengue fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2: Suspected with med. attention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2: Confirmed dengue fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Subject: Suspected dengue fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Subject: Suspected with med. attention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Subject: Confirmed dengue fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs for Antibody Titer Above the Assay Cut Off to Each DEN Serotype for Unprimed and Primed Subjects</title>
        <description>Comparison of F17 and F19 formulations in terms of GMTs at month 7 (one month post dose 2) for each DEN type, -unprimed and primed subjects</description>
        <time_frame>at month 7 (one month post dose 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-DEN-Post-Transfection F17</title>
            <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
          <group group_id="O2">
            <title>T-DEN-Post-Transfection F19</title>
            <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs for Antibody Titer Above the Assay Cut Off to Each DEN Serotype for Unprimed and Primed Subjects</title>
          <description>Comparison of F17 and F19 formulations in terms of GMTs at month 7 (one month post dose 2) for each DEN type, -unprimed and primed subjects</description>
          <units>titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unprimed Subjects: DEN-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.9" lower_limit="84.1" upper_limit="203.7"/>
                    <measurement group_id="O2" value="84.4" lower_limit="43.6" upper_limit="163.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed Subjects: DEN-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.6" lower_limit="125.3" upper_limit="381.3"/>
                    <measurement group_id="O2" value="215.2" lower_limit="116.7" upper_limit="396.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed Subjects: DEN-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.5" lower_limit="76.9" upper_limit="201.6"/>
                    <measurement group_id="O2" value="60.3" lower_limit="33.0" upper_limit="110.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed Subjects: DEN-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377.7" lower_limit="249.4" upper_limit="572.0"/>
                    <measurement group_id="O2" value="105.9" lower_limit="55.8" upper_limit="201.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed Subjects: DEN-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1412.8" lower_limit="1191.5" upper_limit="1675.3"/>
                    <measurement group_id="O2" value="1324.1" lower_limit="1104.1" upper_limit="1587.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed Subjects: DEN-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1514.4" lower_limit="1322.2" upper_limit="1734.6"/>
                    <measurement group_id="O2" value="1338.5" lower_limit="1105.6" upper_limit="1620.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed Subjects: DEN-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1130.0" lower_limit="920.0" upper_limit="1388.0"/>
                    <measurement group_id="O2" value="901.4" lower_limit="707.6" upper_limit="1148.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed Subjects: DEN-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1228.4" lower_limit="1014.1" upper_limit="1488.0"/>
                    <measurement group_id="O2" value="1020.8" lower_limit="809.5" upper_limit="1287.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Neut. Antibody Titer Above the Assay Cut-off to All Dengue Serotypes</title>
        <description>Monovalent, bivalent, trivalent and tetravalent response for DEN neut. antibodies for unprimed and primed subjects</description>
        <time_frame>Pre-vaccination, at post dose 1, months 3 and 6 and post dose 2, month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>F17: Pre-vaccination</title>
            <description>Pre-vaccination (blood sample taken before dose 1)</description>
          </group>
          <group group_id="O2">
            <title>F17 PI (M3)</title>
            <description>Post-Transfection F-17 Post-dose 1, month 3</description>
          </group>
          <group group_id="O3">
            <title>F17 PI (M6)</title>
            <description>Post-Transfection F-17 Post-dose 1, month 6</description>
          </group>
          <group group_id="O4">
            <title>F17 PII (M7)</title>
            <description>Post-Transfection F-17 Post-dose 2, month 7</description>
          </group>
          <group group_id="O5">
            <title>F19: Pre-vaccination</title>
            <description>Pre-vaccination (blood sample taken before dose 1)</description>
          </group>
          <group group_id="O6">
            <title>F19 PI (M3)</title>
            <description>Post-Transfection F-19 Post-dose 1, month 3</description>
          </group>
          <group group_id="O7">
            <title>F19 PI (M6)</title>
            <description>Post-Transfection F-19 Post-dose 1, month 6</description>
          </group>
          <group group_id="O8">
            <title>F19 PII (M7)</title>
            <description>Post-Transfection F-19 Post-dose 2, month 7</description>
          </group>
          <group group_id="O9">
            <title>Placebo: Pre-vaccination</title>
            <description>Pre-vaccination (blood sample taken before dose 1)</description>
          </group>
          <group group_id="O10">
            <title>Placebo: PI (M3)</title>
            <description>Placebo control Post-dose 1, month 3</description>
          </group>
          <group group_id="O11">
            <title>Placebo: PI (M6)</title>
            <description>Placebo control Post-dose 1, month 6</description>
          </group>
          <group group_id="O12">
            <title>Placebo: PII (M7)</title>
            <description>Placebo control Post-dose 2, month 7</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Neut. Antibody Titer Above the Assay Cut-off to All Dengue Serotypes</title>
          <description>Monovalent, bivalent, trivalent and tetravalent response for DEN neut. antibodies for unprimed and primed subjects</description>
          <units>% of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="74"/>
                <count group_id="O10" value="71"/>
                <count group_id="O11" value="69"/>
                <count group_id="O12" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unprimed: Valence=None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="53" lower_limit="41.7" upper_limit="64.1"/>
                    <measurement group_id="O3" value="52.4" lower_limit="41.1" upper_limit="63.6"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.3" upper_limit="8.5"/>
                    <measurement group_id="O5" value="100" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O6" value="50" lower_limit="36.8" upper_limit="63.2"/>
                    <measurement group_id="O7" value="50.8" lower_limit="37.5" upper_limit="64.1"/>
                    <measurement group_id="O8" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O9" value="100" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O10" value="95.8" lower_limit="88.1" upper_limit="99.1"/>
                    <measurement group_id="O11" value="92.8" lower_limit="83.9" upper_limit="97.6"/>
                    <measurement group_id="O12" value="94.1" lower_limit="85.6" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: Valence=Monovalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="24.1" lower_limit="15.4" upper_limit="34.7"/>
                    <measurement group_id="O3" value="23.2" lower_limit="14.6" upper_limit="33.8"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="23.3" lower_limit="13.4" upper_limit="36.0"/>
                    <measurement group_id="O7" value="27.1" lower_limit="16.4" upper_limit="40.3"/>
                    <measurement group_id="O8" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O10" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O11" value="1.4" lower_limit="0.0" upper_limit="7.8"/>
                    <measurement group_id="O12" value="1.5" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: Valence=Bivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.3" upper_limit="11.9"/>
                    <measurement group_id="O3" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.3" upper_limit="8.5"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="5" lower_limit="1.0" upper_limit="13.9"/>
                    <measurement group_id="O7" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O8" value="8.5" lower_limit="2.8" upper_limit="18.7"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O10" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O11" value="2.9" lower_limit="0.4" upper_limit="10.1"/>
                    <measurement group_id="O12" value="1.5" lower_limit="0.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: Valence=Trivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="7.2" lower_limit="2.7" upper_limit="15.1"/>
                    <measurement group_id="O3" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                    <measurement group_id="O4" value="7.3" lower_limit="2.7" upper_limit="15.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="1.7" lower_limit="0.0" upper_limit="8.9"/>
                    <measurement group_id="O7" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O8" value="6.8" lower_limit="1.9" upper_limit="16.5"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O10" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O12" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: Valence=Tetravalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="10.8" lower_limit="5.1" upper_limit="19.6"/>
                    <measurement group_id="O3" value="9.8" lower_limit="4.3" upper_limit="18.3"/>
                    <measurement group_id="O4" value="86.6" lower_limit="77.3" upper_limit="93.1"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="20" lower_limit="10.8" upper_limit="32.3"/>
                    <measurement group_id="O7" value="13.6" lower_limit="6.0" upper_limit="25.0"/>
                    <measurement group_id="O8" value="74.6" lower_limit="61.6" upper_limit="85.0"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O10" value="4.2" lower_limit="0.9" upper_limit="11.9"/>
                    <measurement group_id="O11" value="2.9" lower_limit="0.4" upper_limit="10.1"/>
                    <measurement group_id="O12" value="2.9" lower_limit="0.4" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: Valence=Monovalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.7" upper_limit="9.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="2.1" lower_limit="0.3" upper_limit="7.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="1.1" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O9" value="8.9" lower_limit="4.2" upper_limit="16.2"/>
                    <measurement group_id="O10" value="3" lower_limit="0.6" upper_limit="8.6"/>
                    <measurement group_id="O11" value="3" lower_limit="0.6" upper_limit="8.6"/>
                    <measurement group_id="O12" value="2" lower_limit="0.2" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: Valence=Trivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="2.1" lower_limit="0.3" upper_limit="7.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O10" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O11" value="2" lower_limit="0.2" upper_limit="7.1"/>
                    <measurement group_id="O12" value="1" lower_limit="0.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: Valence=Bivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.7" upper_limit="9.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="1" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O10" value="2" lower_limit="0.2" upper_limit="7.1"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O12" value="1" lower_limit="0.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: Valence=Tetravalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="89.1" upper_limit="98.8"/>
                    <measurement group_id="O2" value="96.6" lower_limit="90.4" upper_limit="99.3"/>
                    <measurement group_id="O3" value="97.7" lower_limit="91.9" upper_limit="99.7"/>
                    <measurement group_id="O4" value="100" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O5" value="92.6" lower_limit="85.3" upper_limit="97.0"/>
                    <measurement group_id="O6" value="98.9" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="98.9" lower_limit="94.0" upper_limit="100.0"/>
                    <measurement group_id="O9" value="90.1" lower_limit="82.5" upper_limit="95.1"/>
                    <measurement group_id="O10" value="91.9" lower_limit="84.7" upper_limit="96.4"/>
                    <measurement group_id="O11" value="89.9" lower_limit="82.2" upper_limit="95.0"/>
                    <measurement group_id="O12" value="90.9" lower_limit="84.4" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: Valence=None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="5.8"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O10" value="3" lower_limit="0.6" upper_limit="8.6"/>
                    <measurement group_id="O11" value="5.1" lower_limit="1.7" upper_limit="11.4"/>
                    <measurement group_id="O12" value="5.1" lower_limit="1.7" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Neut. Sero-response to Each DEN Serotype</title>
        <description>Seropositivity rates for DEN neut. antibodies for unprimed and primed subjects</description>
        <time_frame>Pre-accination, at post dose 1, months 3 and 6 and post dose 2, month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>F17: Pre-vaccination</title>
            <description>Pre-vaccination (blood sample taken before dose 1)</description>
          </group>
          <group group_id="O2">
            <title>F17 PI (M3)</title>
            <description>Post-Transfection F-17 Post-dose 1, month 3</description>
          </group>
          <group group_id="O3">
            <title>F17 PI (M6)</title>
            <description>Post-Transfection F-17 Post-dose 1, month 6</description>
          </group>
          <group group_id="O4">
            <title>F17 PII (M7)</title>
            <description>Post-Transfection F-17 Post-dose 2, month 7</description>
          </group>
          <group group_id="O5">
            <title>F19: Pre-vaccination</title>
            <description>Pre-vaccination (blood sample taken before dose 1)</description>
          </group>
          <group group_id="O6">
            <title>F19 PI (M3)</title>
            <description>Post-Transfection F-19 Post-dose 1, month 3</description>
          </group>
          <group group_id="O7">
            <title>F19 PI (M6)</title>
            <description>Post-Transfection F-19 Post-dose 1, month 6</description>
          </group>
          <group group_id="O8">
            <title>F19 PII (M7)</title>
            <description>Post-Transfection F-19 Post-dose 2, month 7</description>
          </group>
          <group group_id="O9">
            <title>Placebo: Pre-vaccination</title>
            <description>Pre-vaccination (blood sample taken before dose 1)</description>
          </group>
          <group group_id="O10">
            <title>Placebo: PI (M3)</title>
            <description>Placebo control Post-dose 1, month 3</description>
          </group>
          <group group_id="O11">
            <title>Placebo: PI (M6)</title>
            <description>Placebo control Post-dose 1, month 6</description>
          </group>
          <group group_id="O12">
            <title>Placebo: PII (M7)</title>
            <description>Placebo control Post-dose 2, month 7</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Neut. Sero-response to Each DEN Serotype</title>
          <description>Seropositivity rates for DEN neut. antibodies for unprimed and primed subjects</description>
          <units>percent of subject with attribute</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="74"/>
                <count group_id="O10" value="71"/>
                <count group_id="O11" value="69"/>
                <count group_id="O12" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unprimed: DEN-1, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="20.5" lower_limit="12.4" upper_limit="30.8"/>
                    <measurement group_id="O3" value="22.0" lower_limit="13.6" upper_limit="32.5"/>
                    <measurement group_id="O4" value="95.1" lower_limit="88.0" upper_limit="98.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O6" value="26.7" lower_limit="16.1" upper_limit="39.7"/>
                    <measurement group_id="O7" value="18.6" lower_limit="9.7" upper_limit="30.9"/>
                    <measurement group_id="O8" value="83.1" lower_limit="71.0" upper_limit="91.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O10" value="4.2" lower_limit="0.9" upper_limit="11.9"/>
                    <measurement group_id="O11" value="4.3" lower_limit="0.9" upper_limit="12.2"/>
                    <measurement group_id="O12" value="4.4" lower_limit="0.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: DEN-2, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="26.5" lower_limit="17.4" upper_limit="37.3"/>
                    <measurement group_id="O3" value="28.0" lower_limit="18.7" upper_limit="39.1"/>
                    <measurement group_id="O4" value="89.0" lower_limit="80.2" upper_limit="94.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O6" value="43.3" lower_limit="30.6" upper_limit="56.8"/>
                    <measurement group_id="O7" value="40.7" lower_limit="28.1" upper_limit="54.3"/>
                    <measurement group_id="O8" value="93.2" lower_limit="83.5" upper_limit="98.1"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O10" value="4.2" lower_limit="0.9" upper_limit="11.9"/>
                    <measurement group_id="O11" value="4.3" lower_limit="0.9" upper_limit="12.2"/>
                    <measurement group_id="O12" value="2.9" lower_limit="0.4" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: DEN-3, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="14.5" lower_limit="7.7" upper_limit="23.9"/>
                    <measurement group_id="O3" value="15.9" lower_limit="8.7" upper_limit="25.6"/>
                    <measurement group_id="O4" value="92.7" lower_limit="84.8" upper_limit="97.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O6" value="21.7" lower_limit="12.1" upper_limit="34.2"/>
                    <measurement group_id="O7" value="16.9" lower_limit="8.4" upper_limit="29.0"/>
                    <measurement group_id="O8" value="78.0" lower_limit="65.3" upper_limit="87.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O10" value="4.2" lower_limit="0.9" upper_limit="11.9"/>
                    <measurement group_id="O11" value="7.2" lower_limit="2.4" upper_limit="16.1"/>
                    <measurement group_id="O12" value="4.4" lower_limit="0.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprimed: DEN-4, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="37.3" lower_limit="27.0" upper_limit="48.7"/>
                    <measurement group_id="O3" value="32.9" lower_limit="22.9" upper_limit="44.2"/>
                    <measurement group_id="O4" value="97.6" lower_limit="91.5" upper_limit="99.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O6" value="26.7" lower_limit="16.1" upper_limit="39.7"/>
                    <measurement group_id="O7" value="25.4" lower_limit="15.0" upper_limit="38.4"/>
                    <measurement group_id="O8" value="86.4" lower_limit="75.0" upper_limit="94.0"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O10" value="4.2" lower_limit="0.9" upper_limit="11.9"/>
                    <measurement group_id="O11" value="2.9" lower_limit="0.4" upper_limit="10.1"/>
                    <measurement group_id="O12" value="4.4" lower_limit="0.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: DEN-1, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="92.3" upper_limit="99.7"/>
                    <measurement group_id="O2" value="97.7" lower_limit="92.0" upper_limit="99.7"/>
                    <measurement group_id="O3" value="98.9" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O5" value="96.8" lower_limit="91.0" upper_limit="99.3"/>
                    <measurement group_id="O6" value="98.9" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="96.0" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="96.0" upper_limit="100"/>
                    <measurement group_id="O9" value="94.1" lower_limit="87.5" upper_limit="97.8"/>
                    <measurement group_id="O10" value="94.9" lower_limit="88.6" upper_limit="98.3"/>
                    <measurement group_id="O11" value="92.9" lower_limit="86.0" upper_limit="97.1"/>
                    <measurement group_id="O12" value="90.9" lower_limit="83.4" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: DEN-2, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="92.3" upper_limit="99.7"/>
                    <measurement group_id="O2" value="96.6" lower_limit="90.4" upper_limit="99.3"/>
                    <measurement group_id="O3" value="97.7" lower_limit="91.9" upper_limit="99.7"/>
                    <measurement group_id="O4" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O5" value="96.8" lower_limit="91.0" upper_limit="99.3"/>
                    <measurement group_id="O6" value="98.9" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="96.0" upper_limit="100"/>
                    <measurement group_id="O8" value="98.9" lower_limit="94.0" upper_limit="100"/>
                    <measurement group_id="O9" value="95.0" lower_limit="88.8" upper_limit="98.4"/>
                    <measurement group_id="O10" value="93.9" lower_limit="87.3" upper_limit="97.7"/>
                    <measurement group_id="O11" value="92.9" lower_limit="86.0" upper_limit="97.1"/>
                    <measurement group_id="O12" value="93.9" lower_limit="87.3" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: DEN-3, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="90.7" upper_limit="99.3"/>
                    <measurement group_id="O2" value="96.6" lower_limit="90.4" upper_limit="99.3"/>
                    <measurement group_id="O3" value="97.7" lower_limit="91.9" upper_limit="99.7"/>
                    <measurement group_id="O4" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O5" value="92.6" lower_limit="85.3" upper_limit="97.0"/>
                    <measurement group_id="O6" value="98.9" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="96.0" upper_limit="100"/>
                    <measurement group_id="O8" value="98.9" lower_limit="94.0" upper_limit="100"/>
                    <measurement group_id="O9" value="90.1" lower_limit="82.5" upper_limit="95.1"/>
                    <measurement group_id="O10" value="91.9" lower_limit="84.7" upper_limit="96.4"/>
                    <measurement group_id="O11" value="90.9" lower_limit="83.4" upper_limit="95.8"/>
                    <measurement group_id="O12" value="92.9" lower_limit="86.0" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primed: DEN-4, &gt;10 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="90.7" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.9" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O3" value="98.9" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O5" value="98.9" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O6" value="98.9" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="96.0" upper_limit="100"/>
                    <measurement group_id="O8" value="98.9" lower_limit="94.0" upper_limit="100"/>
                    <measurement group_id="O9" value="92.1" lower_limit="85.0" upper_limit="96.5"/>
                    <measurement group_id="O10" value="93.9" lower_limit="87.3" upper_limit="97.7"/>
                    <measurement group_id="O11" value="91.9" lower_limit="84.7" upper_limit="96.4"/>
                    <measurement group_id="O12" value="92.9" lower_limit="86.0" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response to DEN Antibody at Post Dose 1, Month 3</title>
        <description>Vaccine response for DEN-1, DEN-2, DEN-3 and DEN-4 antibody
S- = seronegative subjects (antibody titer &lt;10 ED50 for DEN-1, 2, 3, and 4 prior to vaccination; S+ = Seropositive subjects (antibody titer &gt;10 ED50 for DEN-1, 2, 3 and 4 prior to vaccination; Total = subjects either seropositive or seronegative at pre-vaccination
Vaccine response defined as: For initially seronegative subjects, antibody titer &gt;10 ED50 at PI(M3) and for initially seropositive subjects: antibody titer at PI(m3) &gt;4 fold the pre-vaccination antibody titer</description>
        <time_frame>at month 3, post dose 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DEN-1, F17, S-</title>
            <description>Antibody DEN-1, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O2">
            <title>DEN-1, F17, S+</title>
            <description>Antibody DEN-1, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O3">
            <title>DEN-1, F17, Total</title>
            <description>Antibody DEN-1, Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O4">
            <title>DEN-1, F19, S-</title>
            <description>Antibody DEN-1, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O5">
            <title>DEN-1, F19, S+</title>
            <description>Antibody DEN-1, Group F19, Pre-vaccination group = S+</description>
          </group>
          <group group_id="O6">
            <title>DEN-1, F19, Total</title>
            <description>Antibody DEN-1, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O7">
            <title>DEN-1, Placebo, S-</title>
            <description>Antibody DEN-1, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O8">
            <title>DEN-1, Placebo, S+</title>
            <description>Antibody DEN-1, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O9">
            <title>DEN-1, Placebo, Total</title>
            <description>Antibody DEN-1, Placebo group, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O10">
            <title>DEN-2, F17, S-</title>
            <description>Antibody DEN-2, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O11">
            <title>DEN-2, F17, S+</title>
            <description>Antibody DEN-2, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O12">
            <title>DEN-2, F17, Total</title>
            <description>Antibody DEN-2,. Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O13">
            <title>DEN-2, F19, S-</title>
            <description>Antibody DEN-2, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O14">
            <title>DEN-2, F19, S+</title>
            <description>Antibody DEN-2, Group F19, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O15">
            <title>DEN-2, F19, Total</title>
            <description>Antibody DEN-2, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O16">
            <title>DEN-2, Placebo, S-</title>
            <description>Antibody DEN-2, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O17">
            <title>DEN-2, Placebo, S+</title>
            <description>Antibody DEN-2, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O18">
            <title>DEN-2, Placebo, Total</title>
            <description>Antibody DEN-2, Placebo group, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O19">
            <title>DEN-3, F17, S-</title>
            <description>Antibody DEN-3, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O20">
            <title>DEN-3, F17, S+</title>
            <description>Antibody DEN-3, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O21">
            <title>DEN-3, F17, Total</title>
            <description>Antibody DEN-3, Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O22">
            <title>DEN-3, F19, S-</title>
            <description>Antibody DEN-3, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O23">
            <title>DEN-3, F19, S+</title>
            <description>Antibody DEN-3, Group F19, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O24">
            <title>DEN-3, F19, Total</title>
            <description>Antibody DEN-3, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O25">
            <title>DEN-3, Placebo, S-</title>
            <description>Antibody DEN-3, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O26">
            <title>DEN-3, Placebo, S+</title>
            <description>Antibody DEN-3, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O27">
            <title>DEN-3, Placebo, Total</title>
            <description>Antibody DEN-3, Placebo group, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O28">
            <title>DEN-4, F17, S-</title>
            <description>Antibody DEN-4, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O29">
            <title>DEN-4, F17, S+</title>
            <description>Antibody DEN-4, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O30">
            <title>DEN-4, F17, Total</title>
            <description>Antibody DEN-4, Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O31">
            <title>DEN-4, F19, S-</title>
            <description>Antibody DEN-4, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O32">
            <title>DEN-4, F19, S+</title>
            <description>Antibody DEN-4, Group F19, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O33">
            <title>DEN-4, F19, Total</title>
            <description>Antibody DEN-4, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O34">
            <title>DEN-4, Placebo, S-</title>
            <description>Antibody DEN-4, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O35">
            <title>DEN-4, Placebo, S+</title>
            <description>Antibody DEN-4, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O36">
            <title>DEN-4, Placebo, Total</title>
            <description>Antibody DEN-4, Placebo group, Pre-vaccination status = Total</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Response to DEN Antibody at Post Dose 1, Month 3</title>
          <description>Vaccine response for DEN-1, DEN-2, DEN-3 and DEN-4 antibody
S- = seronegative subjects (antibody titer &lt;10 ED50 for DEN-1, 2, 3, and 4 prior to vaccination; S+ = Seropositive subjects (antibody titer &gt;10 ED50 for DEN-1, 2, 3 and 4 prior to vaccination; Total = subjects either seropositive or seronegative at pre-vaccination
Vaccine response defined as: For initially seronegative subjects, antibody titer &gt;10 ED50 at PI(M3) and for initially seropositive subjects: antibody titer at PI(m3) &gt;4 fold the pre-vaccination antibody titer</description>
          <units>% of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="101"/>
                <count group_id="O7" value="77"/>
                <count group_id="O8" value="43"/>
                <count group_id="O9" value="120"/>
                <count group_id="O10" value="85"/>
                <count group_id="O11" value="33"/>
                <count group_id="O12" value="118"/>
                <count group_id="O13" value="63"/>
                <count group_id="O14" value="45"/>
                <count group_id="O15" value="108"/>
                <count group_id="O16" value="76"/>
                <count group_id="O17" value="43"/>
                <count group_id="O18" value="119"/>
                <count group_id="O19" value="85"/>
                <count group_id="O20" value="36"/>
                <count group_id="O21" value="121"/>
                <count group_id="O22" value="66"/>
                <count group_id="O23" value="45"/>
                <count group_id="O24" value="111"/>
                <count group_id="O25" value="81"/>
                <count group_id="O26" value="39"/>
                <count group_id="O27" value="120"/>
                <count group_id="O28" value="85"/>
                <count group_id="O29" value="42"/>
                <count group_id="O30" value="127"/>
                <count group_id="O31" value="61"/>
                <count group_id="O32" value="49"/>
                <count group_id="O33" value="110"/>
                <count group_id="O34" value="79"/>
                <count group_id="O35" value="45"/>
                <count group_id="O36" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="12.3" upper_limit="30.4"/>
                    <measurement group_id="O2" value="54.1" lower_limit="36.9" upper_limit="70.5"/>
                    <measurement group_id="O3" value="30.6" lower_limit="22.5" upper_limit="39.6"/>
                    <measurement group_id="O4" value="30.2" lower_limit="19.2" upper_limit="43.0"/>
                    <measurement group_id="O5" value="73.7" lower_limit="56.9" upper_limit="86.6"/>
                    <measurement group_id="O6" value="46.5" lower_limit="36.5" upper_limit="56.7"/>
                    <measurement group_id="O7" value="7.8" lower_limit="2.9" upper_limit="16.2"/>
                    <measurement group_id="O8" value="7.0" lower_limit="1.5" upper_limit="19.1"/>
                    <measurement group_id="O9" value="7.5" lower_limit="3.5" upper_limit="13.8"/>
                    <measurement group_id="O10" value="25.9" lower_limit="17.0" upper_limit="36.5"/>
                    <measurement group_id="O11" value="63.6" lower_limit="45.1" upper_limit="79.6"/>
                    <measurement group_id="O12" value="36.4" lower_limit="27.8" upper_limit="45.8"/>
                    <measurement group_id="O13" value="46.0" lower_limit="33.4" upper_limit="59.1"/>
                    <measurement group_id="O14" value="64.4" lower_limit="48.8" upper_limit="78.1"/>
                    <measurement group_id="O15" value="53.7" lower_limit="43.8" upper_limit="63.3"/>
                    <measurement group_id="O16" value="3.9" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O17" value="14.0" lower_limit="5.3" upper_limit="27.9"/>
                    <measurement group_id="O18" value="7.6" lower_limit="3.5" upper_limit="13.9"/>
                    <measurement group_id="O19" value="15.3" lower_limit="8.4" upper_limit="24.7"/>
                    <measurement group_id="O20" value="61.1" lower_limit="43.5" upper_limit="76.9"/>
                    <measurement group_id="O21" value="28.9" lower_limit="21.0" upper_limit="37.9"/>
                    <measurement group_id="O22" value="28.8" lower_limit="18.3" upper_limit="41.3"/>
                    <measurement group_id="O23" value="62.2" lower_limit="46.5" upper_limit="76.2"/>
                    <measurement group_id="O24" value="42.3" lower_limit="33.0" upper_limit="52.1"/>
                    <measurement group_id="O25" value="6.2" lower_limit="2.0" upper_limit="13.8"/>
                    <measurement group_id="O26" value="5.1" lower_limit="0.6" upper_limit="17.3"/>
                    <measurement group_id="O27" value="5.8" lower_limit="2.4" upper_limit="11.6"/>
                    <measurement group_id="O28" value="38.8" lower_limit="28.4" upper_limit="50.0"/>
                    <measurement group_id="O29" value="52.4" lower_limit="36.4" upper_limit="68.0"/>
                    <measurement group_id="O30" value="43.3" lower_limit="34.5" upper_limit="52.4"/>
                    <measurement group_id="O31" value="27.9" lower_limit="17.1" upper_limit="40.8"/>
                    <measurement group_id="O32" value="65.3" lower_limit="50.4" upper_limit="78.3"/>
                    <measurement group_id="O33" value="44.5" lower_limit="35.1" upper_limit="54.3"/>
                    <measurement group_id="O34" value="7.6" lower_limit="2.8" upper_limit="15.8"/>
                    <measurement group_id="O35" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O36" value="8.9" lower_limit="4.5" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response to DEN Antibody at Post Dose 2, Month 7</title>
        <description>Vaccine response for DEN-1, DEN2, DEN-3, DEN-4 antibody at post dose 2, month 7</description>
        <time_frame>at month 7, post dose 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DEN-1, F17, S-</title>
            <description>Antibody DEN-1, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O2">
            <title>DEN-1, F17, S+</title>
            <description>Antibody DEN-1, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O3">
            <title>DEN-1, F17, Total</title>
            <description>Antibody DEN-1, Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O4">
            <title>DEN-1, F19, S-</title>
            <description>Antibody DEN-1, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O5">
            <title>DEN-1, F19, S+</title>
            <description>Antibody DEN-1, Group F19, Pre-vaccination group = S+</description>
          </group>
          <group group_id="O6">
            <title>DEN-1, F19, Total</title>
            <description>Antibody DEN-1, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O7">
            <title>DEN-1, Placebo, S-</title>
            <description>Antibody DEN-1, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O8">
            <title>DEN-1, Placebo, S+</title>
            <description>Antibody DEN-1, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O9">
            <title>DEN-1, Placebo, Total</title>
            <description>Antibody DEN-1, Placebo group, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O10">
            <title>DEN-2, F17, S-</title>
            <description>Antibody DEN-2, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O11">
            <title>DEN-2, F17, S+</title>
            <description>Antibody DEN-2, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O12">
            <title>DEN-2, F17, Total</title>
            <description>Antibody DEN-2,. Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O13">
            <title>DEN-2, F19, S-</title>
            <description>Antibody DEN-2, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O14">
            <title>DEN-2, F19, S+</title>
            <description>Antibody DEN-2, Group F19, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O15">
            <title>DEN-2, F19, Total</title>
            <description>Antibody DEN-2, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O16">
            <title>DEN-2, Placebo, S-</title>
            <description>Antibody DEN-2, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O17">
            <title>DEN-2, Placebo, S+</title>
            <description>Antibody DEN-2, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O18">
            <title>DEN-2, Placebo, Total</title>
            <description>Antibody DEN-2, Placebo group, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O19">
            <title>DEN-3, F17, S-</title>
            <description>Antibody DEN-3, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O20">
            <title>DEN-3, F17, S+</title>
            <description>Antibody DEN-3, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O21">
            <title>DEN-3, F17, Total</title>
            <description>Antibody DEN-3, Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O22">
            <title>DEN-3, F19, S-</title>
            <description>Antibody DEN-3, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O23">
            <title>DEN-3, F19, S+</title>
            <description>Antibody DEN-3, Group F19, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O24">
            <title>DEN-3, F19, Total</title>
            <description>Antibody DEN-3, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O25">
            <title>DEN-3, Placebo, S-</title>
            <description>Antibody DEN-3, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O26">
            <title>DEN-3, Placebo, S+</title>
            <description>Antibody DEN-3, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O27">
            <title>DEN-3, Placebo, Total</title>
            <description>Antibody DEN-3, Placebo group, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O28">
            <title>DEN-4, F17, S-</title>
            <description>Antibody DEN-4, Group F17, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O29">
            <title>DEN-4, F17, S+</title>
            <description>Antibody DEN-4, Group F17, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O30">
            <title>DEN-4, F17, Total</title>
            <description>Antibody DEN-4, Group F17, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O31">
            <title>DEN-4, F19, S-</title>
            <description>Antibody DEN-4, Group F19, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O32">
            <title>DEN-4, F19, S+</title>
            <description>Antibody DEN-4, Group F19, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O33">
            <title>DEN-4, F19, Total</title>
            <description>Antibody DEN-4, Group F19, Pre-vaccination status = Total</description>
          </group>
          <group group_id="O34">
            <title>DEN-4, Placebo, S-</title>
            <description>Antibody DEN-4, Placebo group, Pre-vaccination status = S-</description>
          </group>
          <group group_id="O35">
            <title>DEN-4, Placebo, S+</title>
            <description>Antibody DEN-4, Placebo group, Pre-vaccination status = S+</description>
          </group>
          <group group_id="O36">
            <title>DEN-4, Placebo, Total</title>
            <description>Antibody DEN-4, Placebo group, Pre-vaccination status = Total</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Response to DEN Antibody at Post Dose 2, Month 7</title>
          <description>Vaccine response for DEN-1, DEN2, DEN-3, DEN-4 antibody at post dose 2, month 7</description>
          <units>% of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="98"/>
                <count group_id="O7" value="74"/>
                <count group_id="O8" value="43"/>
                <count group_id="O9" value="117"/>
                <count group_id="O10" value="84"/>
                <count group_id="O11" value="32"/>
                <count group_id="O12" value="116"/>
                <count group_id="O13" value="62"/>
                <count group_id="O14" value="42"/>
                <count group_id="O15" value="104"/>
                <count group_id="O16" value="73"/>
                <count group_id="O17" value="43"/>
                <count group_id="O18" value="116"/>
                <count group_id="O19" value="84"/>
                <count group_id="O20" value="34"/>
                <count group_id="O21" value="118"/>
                <count group_id="O22" value="64"/>
                <count group_id="O23" value="43"/>
                <count group_id="O24" value="107"/>
                <count group_id="O25" value="78"/>
                <count group_id="O26" value="39"/>
                <count group_id="O27" value="117"/>
                <count group_id="O28" value="84"/>
                <count group_id="O29" value="40"/>
                <count group_id="O30" value="124"/>
                <count group_id="O31" value="60"/>
                <count group_id="O32" value="48"/>
                <count group_id="O33" value="108"/>
                <count group_id="O34" value="76"/>
                <count group_id="O35" value="45"/>
                <count group_id="O36" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="88.1" upper_limit="98.7"/>
                    <measurement group_id="O2" value="60.0" lower_limit="42.1" upper_limit="76.1"/>
                    <measurement group_id="O3" value="84.7" lower_limit="77.0" upper_limit="90.7"/>
                    <measurement group_id="O4" value="83.6" lower_limit="71.9" upper_limit="91.8"/>
                    <measurement group_id="O5" value="75.7" lower_limit="58.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="80.6" lower_limit="71.4" upper_limit="87.9"/>
                    <measurement group_id="O7" value="6.8" lower_limit="2.2" upper_limit="15.1"/>
                    <measurement group_id="O8" value="11.6" lower_limit="3.9" upper_limit="25.1"/>
                    <measurement group_id="O9" value="8.5" lower_limit="4.2" upper_limit="15.2"/>
                    <measurement group_id="O10" value="89.3" lower_limit="80.6" upper_limit="95.0"/>
                    <measurement group_id="O11" value="71.9" lower_limit="53.3" upper_limit="86.3"/>
                    <measurement group_id="O12" value="84.5" lower_limit="76.6" upper_limit="90.5"/>
                    <measurement group_id="O13" value="93.5" lower_limit="84.3" upper_limit="98.2"/>
                    <measurement group_id="O14" value="64.3" lower_limit="48.0" upper_limit="78.4"/>
                    <measurement group_id="O15" value="81.7" lower_limit="72.9" upper_limit="88.6"/>
                    <measurement group_id="O16" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O17" value="14.0" lower_limit="5.3" upper_limit="27.9"/>
                    <measurement group_id="O18" value="7.8" lower_limit="3.6" upper_limit="14.2"/>
                    <measurement group_id="O19" value="92.9" lower_limit="85.1" upper_limit="97.3"/>
                    <measurement group_id="O20" value="47.1" lower_limit="29.8" upper_limit="64.9"/>
                    <measurement group_id="O21" value="79.7" lower_limit="71.3" upper_limit="86.5"/>
                    <measurement group_id="O22" value="79.7" lower_limit="67.8" upper_limit="88.7"/>
                    <measurement group_id="O23" value="48.8" lower_limit="33.3" upper_limit="64.5"/>
                    <measurement group_id="O24" value="67.3" lower_limit="57.5" upper_limit="76.0"/>
                    <measurement group_id="O25" value="9.0" lower_limit="3.7" upper_limit="17.6"/>
                    <measurement group_id="O26" value="15.4" lower_limit="5.9" upper_limit="30.5"/>
                    <measurement group_id="O27" value="11.1" lower_limit="6.1" upper_limit="18.3"/>
                    <measurement group_id="O28" value="97.6" lower_limit="91.7" upper_limit="99.7"/>
                    <measurement group_id="O29" value="57.5" lower_limit="40.9" upper_limit="73.0"/>
                    <measurement group_id="O30" value="84.7" lower_limit="77.1" upper_limit="90.5"/>
                    <measurement group_id="O31" value="86.7" lower_limit="75.4" upper_limit="94.1"/>
                    <measurement group_id="O32" value="68.8" lower_limit="53.7" upper_limit="81.3"/>
                    <measurement group_id="O33" value="78.7" lower_limit="69.8" upper_limit="86.0"/>
                    <measurement group_id="O34" value="7.9" lower_limit="3.0" upper_limit="16.4"/>
                    <measurement group_id="O35" value="6.7" lower_limit="1.4" upper_limit="18.3"/>
                    <measurement group_id="O36" value="7.4" lower_limit="3.5" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T-DEN-Post-Transfection F17</title>
          <description>Post-Transfection F17, full dose
T-DEN-Post-Transfection F17: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
        </group>
        <group group_id="E2">
          <title>T-DEN-Post-Transfection F19</title>
          <description>Post-Transfection F19, full dose
T-DEN-Post-Transfection F19: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Control
Placebo: Lyophilized, single dose vials and sterile water for
&gt; injection; 0.5 mL dose; Vaccination schedule: 0, 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Acute viral gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis (face)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Presumptive viral syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteral calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchial asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="211"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="212"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="211"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="211"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="211"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Abdominal pain (upper)</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="211"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux desease</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tooth development disorder</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="211"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="212"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="211"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="211"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="212"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="211"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="212"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Fever (axillary)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="211"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="212"/>
                <counts group_id="E3" events="47" subjects_affected="47" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="211"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Fever (axillary)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="211"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="212"/>
                <counts group_id="E3" events="36" subjects_affected="36" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Influenza like symptoms</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="211"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="211"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="212"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Conuunctivitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="211"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bruns first degree</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="211"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="211"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="212"/>
                <counts group_id="E3" events="45" subjects_affected="45" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="211"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="212"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Penis disorder</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="211"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="211"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="211"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="212"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 1</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="211"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="212"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="211"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Dose 2</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="211"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash generalized</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>Ages 1 to 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dermititis allergic</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <description>Ages 5 - 50</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Faina Rose, PhD</name_or_title>
      <organization>GSK</organization>
      <phone>610-664-8986</phone>
      <email>faina.v.rose@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

